Industry News

Proteostasis Therapeutics, Inc., a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by dysfunctional protein processing such as cystic fibrosis, today announced the appointment of Naimish Patel, M.D., C.M., and Elizabeth Tullis, M.D., FRCPC, to its clinical advisory board. Patel is currently a Project Leader in Respiratory, Inflammation and Autoimmunity iMED and Senior Medical Director for AstraZeneca..."/>
Proteostasis Therapeutics Appoints Naimish Patel, M.D., C.M., and Elizabeth Tullis, M.D., FRCPC, to its Clinical Advisory Board
Aerie Pharmaceuticals, Inc., today announced that the Company will host a live webcast of its Investor Day taking place on Wednesday, October 5, 2016 at 12:00p.m. ET in New York, NY. To view the slide presentation and listen to the webcast please visit our website at"/>
Aerie Pharmaceuticals to Host Investor Day on October 5, 2016
Versartis reported on Tuesday that it intends to launch an underwritten public offering of shares of its common stock. The company plans to provide the underwriters with a 30- day option to purchase up to another 15% of the number of shares of common stock sold in connection with the offering. Subject to market conditions, there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering."/>
Versartis plans public offering of common shares
Acceleron Pharma stated on Tuesday that Habib Dable has been named as its new president and chief executive officer. Effective 1 December 2016, Dable will succeed current president and CEO John Knopf. Most recently, Dable has served as president of Pharmaceuticals in the US for Bayer AG as well as head of specialty medicine for Bayer HealthCare Pharmaceuticals."/>
Acceleron reports change in executive roles
Ionis Pharmaceuticals, Inc. announced today that Stanley T. Crooke, Ph.D., M.D., founder, CEO and chairman of the board of directors of Ionis Pharmaceuticals, Inc., has been awarded the Lifetime Achievement Award from the Oligonucleotide Therapeutics Society, OTS. The OTS Lifetime Achievement Award recognizes Dr. Crooke's lasting commitment to the field of oligonucleotide therapeutics through outstanding contributions to education,..."/>
Ionis Pharmaceuticals' CEO, Dr. Stanley Crooke, Receives Lifetime Achievement Award from the Oligonucleotide Therapeutics Society
Medical Facilities Corporation announced today that the Corporation's Sioux Falls Specialty Hospital has entered into a definitive agreement to acquire Prairie States Surgical Center, L.L.C., which owns and operates Prairie States Surgical Center, an ambulatory surgical center located in Sioux Falls, South Dakota that specializes in orthopedic procedures. PSSC generated about US $8..."/>
Ambulatory surgery center acquired by unit of Medical Facilities Corporation
Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’ s disease, other central nervous system diseases, pain and various types of cancer, today announced that it has signed a material transfer agreement with Biogen under which Biogen will test Anavex’ s lead drug candidate, ANAVEX 2-73 in an..."/>
Anavex Compound to be Tested in Biogen Neurological Protection Model
Bavarian Nordic A/S today announced the appointment of Dr. Christopher R. Heery, M.D. to the position of Chief Medical Officer. Heery will oversee preclinical and clinical development of the Company's infectious disease and immuno-oncology portfolio."/>
Bavarian Nordic Appoints Christopher Heery, M.D., as Chief Medical Officer
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective broad spectrum therapeutics for the treatment of serious..."/>
Matinas BioPharma Commences Patient Dosing in NIH-Sponsored Phase 2a Study with Lead Anti-Infective Candidate MAT2203
Assembly Biosciences, Inc., a biotechnology company developing novel oral therapeutics for disorders associated with the human microbiome and the treatment of hepatitis B virus infection, today announced new senior level hires who are primarily focused on advancing the company’ s expanding microbiome platform. The new team members include Miguel Barbosa, PhD, as Chief Scientific Officer of the Microbiome Program; George Grandolfi, PhD, as Vice..."/>
Assembly Biosciences Announces Key Additions to Microbiome Team
CTD Holdings, Inc., a biotechnology company that develops cyclodextrin-based products for the treatment of disease, today announced that the company made presentations on its US and UK clinical studies at both the 7 th Interactive Workshop on Niemann-Pick Diseases, and the 23 rd Annual Family Conference hosted by Niemann-Pick UK, a non-profit charity in the United Kingdom dedicated to helping families affected by Niemann-Pick Type C disease."/>
CTD Holdings Presents on Clinical Trials at Niemann-Pick UK Conferences
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today announced that the Company and investigators will be presenting two e-posters at the European Congress on Emergency Medicine, which is being held October 1-5, 2016 in Vienna, Austria. Both e-posters will be displayed on monitors..."/>
AcelRx Pharmaceuticals Presenting ARX-04 Clinical Trial Findings and Cost Analysis at European Congress on Emergency Medicine
MEDNAX company and the leading national teleradiology services and telemedicine company, announced that it has implemented its first breast imaging Live Video Diagnostics solution site at the Center for Women’ s Imaging at Medical Center Hospital using Cisco ® technology. MCH is a 402- bed regional..."/>
Cisco Powers vRad Live Video Diagnostics Solution Site to Eliminate Geographic Boundaries for Breast Imaging, Improve Patient Care with Face-to-Face Collaboration
Athersys, Inc. announced today that it has received agreement from the U.S. Food and Drug Administration under a Special Protocol Assessment for the design and planned analysis of a Phase 3 clinical trial of Athersys’ novel MultiStem ® cell therapy product for the treatment of ischemic stroke. The SPA provides agreement from the FDA that the protocol design, clinical endpoints, planned conduct and statistical analyses encompassed in Athersys’ planned..."/>
Athersys Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Study of MultiStem® Treatment for Ischemic Stroke
Incyte’ s IDO1 inhibitor in combination with Merck’ s anti-PD-1 therapy is well-tolerated and demonstrates durable clinical response in patients with treatment-naïve advanced melanoma. WILMINGTON, Del.---- Incyte Corporation today announced that the European Society for Medical Oncology has published an abstract containing updated data from the Phase 1 portion of the ECHO-202 trial evaluating the safety and efficacy of epacadostat, Incyte’ s selective IDO1 enzyme..."/>
Updated Phase 1 Data Reinforce the Clinical Profile of Epacadostat in Combination with Keytruda® (Pembrolizumab)
EnteroMedics Inc reported on Tuesday the addition of Dan Gladney as chairman of the board of directors. Effective 14 October 2016, Gladney will succeed the company's co-founder, Dr Mark Knudson, who will be retiring from the board. However, Dr Knudson will be special advisor to the CEO on clinical and scientific activities following his retirement."/>
EnteroMedics elects Dan Gladney as board chair
IsoRay, Inc., a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced the launch of its newly redesigned corporate website at The redesigned website introduces IsoRay's new branding and logo and offers quick and easy access to essential information that provides a..."/>
IsoRay, Inc. Announces Launch of Newly Redesigned Patient and Clinician Focused Corporate Website
Ensign Group, Inc., the parent company of the Ensign™ group of skilled nursing, rehabilitative care services, hospice care, assisted living and urgent care companies, today announced that its urgent care subsidiary, Immediate Clinic Seattle, Inc., agreed to terms to sell substantially all of its assets relating to its 14 urgent care operations in the greater Seattle market.. The buyer, MultiCare Health System, is a not-for-profit health care..."/>
The Ensign Group Agrees to Sell Its Urgent Care Operations
Medivation, Inc. today announced that new data from Company-sponsored and investigator-initiated clinical trials will be presented at the European Society for Medical Oncology 2016 Congress, being held October 7-11, in Copenhagen. Presentations include a pilot study of the company's investigational PARP inhibitor talazoparib in patients with BRCA-mutated breast cancer, and analyses of enzalutamide in the advanced prostate cancer setting,..."/>
Medivation Highlights New Data From Differentiated Oncology Portfolio at ESMO 2016
Pfizer Inc. today announced that it will be presenting data from 20 abstracts, including three late-breakers, at the European Society for Medical Oncology 2016 Congress in Copenhagen from October 7-11,..."/>
Pfizer to Showcase Progress of Broad-Based Oncology Portfolio at European Society for Medical Oncology (ESMO) 2016 Congress
Exact Sciences Corp. today announced that the company will host a webcast and conference call on Oct. 26, 2016, to discuss its third-quarter 2016 financial results. Third-Quarter 2016 Webcast and Conference Call Details. An archive of the webcast will be available at"/>
Exact Sciences to host third-quarter 2016 results webcast and call

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology726 Articles
Consumer Discretionary616 Articles
Financials453 Articles
Industrials399 Articles
Health Care389 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at